

# CITATION REPORT

List of articles citing

Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model

DOI: 10.1016/j.jval.2013.12.007  
Value in Health, 2014, 17, 205-14.

**Source:** <https://exaly.com/paper-pdf/59685187/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	New UK model good at predicting AML costs and outcomes. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2014</b> , 700, 8-8	0.1	
16	The Patient Perspective on Living with Acute Myeloid Leukemia. <i>Oncology and Therapy</i> , <b>2016</b> , 4, 225-238	2.7	15
15	Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium. <i>Leukemia Research</i> , <b>2016</b> , 46, 26-9	2.7	7
14	Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 526-35	4.5	8
13	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 39	22.4	28
12	Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. <i>European Journal of Health Economics</i> , <b>2017</b> , 18, 255-267	3.6	12
11	Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 519-527	2.5	22
10	Azacitidine in adult patients with acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 116, 159-177	7	31
9	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 700-700g	7.8	26
8	Systematic Predictive Analysis of Personalized Life Expectancy Using Smart Devices. <i>Technologies</i> , <b>2018</b> , 6, 74	2.4	6
7	Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 69, 224-232	14.4	18
6	Healthcare expenses for treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , <b>2019</b> , 12, 641-650	2.8	9
5	Antitumor synergy with SY-1425, a selective RAR $\alpha$ agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia. <i>Haematologica</i> , <b>2019</b> , 104, e138-e142	6.6	7
4	Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain. <i>ClinicoEconomics and Outcomes Research</i> , <b>2021</b> , 13, 263-277	1.7	2
3	Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis. <i>Ontario Health Technology Assessment Series</i> , <b>2016</b> , 16, 1-83	3.1	2
2	‘If I don’t work, I don’t get paid’ An Australian qualitative exploration of the financial impacts of acute myeloid leukaemia. <i>Health and Social Care in the Community</i> , <b>2021</b> ,	2.6	0
1	Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States.		0

